How Genetic Discoveries Lead to Parkinson's Therapies

This is an archived file of an event that took place on January 18, 2018.

With ongoing trials targeting genetic links to Parkinson's (alpha-synuclein, GBA and LRRK2), we discuss how we go from discovering genes to creating precision therapies. And we talk about why you should participate in genetic research even if you don't carry a known Parkinson's genetic mutation.

Title: How Genetic Discoveries Lead to Parkinson's Therapies

Duration: 1 hour

Continuing Medical Education Information for Health Care Professionals

MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: January 18, 2018
Date CME Credit No Longer Available: January 18, 2020

Learning Objectives

  1. Describe researchers' current understanding of Parkinson's disease (PD) genetics. 
  2. Recognize the relationship between genes and cellular proteins. 
  3. Discuss how scientists map genes to proteins to new potential therapies. 
  4. Identify how and why people, even those who don't have a known PD-associated mutation, can participate in PD genetic research.

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Dave Iverson
Nothing to disclose

Roy Alcalay, MD, MSc
Assistant Professor of Neurology
Columbia University
Nothing to disclose

Andrew Singleton, PhD
Chief, Laboratory of Neurogenetics
National Institute on Aging
National Institutes of Health
Nothing to disclose

Anna Cohn Donnelly, DPH
Person with Parkinson's
Member, MJFF Patient Council
Nothing to disclose


Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.

By registering you agree to receive email updates from
The Michael J. Fox Foundation. You can unsubscribe any time.